Exton-based Immunome to merge with Seattle-based company to continue cancer care

Seattle biotech company MorphImmune is set to be acquired by Immunome, a biopharmaceutical firm based in Pennsylvania. As both organizations specialize in oncology, the move aims to increase resources and enhance development and discovery.

The acquisition has yet to be approved by shareholders. Immunome will assume control of 55% of the company, with MorphImmune taking the remainder. The new headquarters will be based in Seattle.

“This is the first step in establishing a preeminent oncology company,” MorphImmune CEO Clay B. Siegall said. “Combining MorphImmune’s platform with Immunome’s [drug-]discovery engine will enable us to pursue novel targets and modalities.”

(Photo: Purnanand Sarma, CEO,  Immunome)

READ THE STORY at Vista Today »